Abbott(ABT)
Search documents
Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression
Prnewswire· 2024-09-04 13:00
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating conditionApproximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the T ...
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
ZACKS· 2024-09-03 22:50
The most recent trading session ended with Abbott (ABT) standing at $114.66, reflecting a +1.23% shift from the previouse trading day's closing. This change outpaced the S&P 500's 2.12% loss on the day. At the same time, the Dow lost 1.51%, and the tech-heavy Nasdaq lost 3.26%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.27% over the past month, lagging the Medical sector's gain of 5.45% and the S&P 500's gain of 5.78% in that time.Investors will be eager ...
Why Abbott Stock Looks More Attractive Than Its Medical Devices Peer
Forbes· 2024-09-03 09:00
LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. CES, the world's largest annual consumer technology trade show, runs through January 12 and features about 4,000 exhibitors showing off their latest products and services to more than 130,000 attendees. (Photo by Ethan Miller/Getty Images)Getty ImagesGiven its better prospects, we believe Abbott stock (NYSE: ABT) is a better p ...
3 Fortune 500 Industry Leaders Boast Ideal August Dividends
Seeking Alpha· 2024-08-31 09:17
smrm1977 Foreword This article is based on Fortune magazine’s 2024 survey of 500 Largest U.S. Corporations (F500-IL) “The Fortune 500, in its 70th year, ranked the biggest U.S. companies by revenue. In total, Fortune 500 companies represented two-thirds of the U.S. GDP with $18.8 trillion in revenues, $1.7 trillion in profits, and $43 trillion in market value (as of March 28, 2024), and they employed 31 million people worldwide.” This article covers the top profit-generating companies in 66-industries. ...
10 High-Yield A-Rated Blue-Chips For Potentially Scary Times Ahead
Seeking Alpha· 2024-08-30 11:00
tiero No Recession Today Doesn't Mean You Can Be Complacent To paraphrase Thomas Jefferson, "The price of financial liberty is eternal vigilance." Just because the economy today is good and not likely to get much worse in the future doesn't mean long-term investors can rest easily. Dividend Kings S&P Valuation Tool You never have to worry about the economy if you have an optimized long-term investment plan. Part of that plan is to select companies adaptable to changing economic and regulatory conditi ...
My Best Dividend Aristocrats For September 2024
Seeking Alpha· 2024-08-28 15:42
Dilok Klaisataporn 2024 Review The second half of 2024 kicks off on a bright note for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) as the fund gained 5.15% in July. This brought the year-to-date return for the ETF up to 7.21% through the month-end of July. The SPDR S&P 500 ETF Trust (SPY) posted a gain of only 1.21% in July, however, year-to-date it is outpacing the aristocrats by a wide margin, up 16.62%. The trend from July has thus far extended into August. NOBL is up 2.63% through August 27th, ...
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
ZACKS· 2024-08-28 14:46
Abbott Laboratories (ABT) recently announced the expansion of its Pure Blissby Similacline of organic and European-made infant formulas. This line offers parents a variety of products to meet specific formula preferences.The expansion of Pure Bliss' line of products highlights Abbott’s motive to invest in clinical research and product development to advance nutrition science for babies of all ages.About Abbott’s Pure Bliss LinePure Bliss by Similac offers a range of organic or European-made infant formulas ...
Abbott's Core Businesses Thrive Despite Macroeconomic Issues
ZACKS· 2024-08-27 16:05
Abbott’s (ABT) diversified business portfolio is well-positioned to drive continued momentum in 2024. However, Abbott is facing a challenging business environment globally. ABT currently carries a Zacks Rank #3 (Hold).Abbott continues to expand its Diagnostics business foothold (consisting of 21.2% of the total revenues in the second quarter of 2024). Over the past few quarters, the company has witnessed increased demand for routine diagnostics (excluding COVID-19 testing sales), particularly in the United ...
Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores
Prnewswire· 2024-08-27 13:00
Pure Bliss™ Organic and Pure Bliss Organic with A2 Milk infant formulas – both USDA-certified – are now part of the Pure Bliss by Similac® line that includes European-made Pure Bliss Irish Farms, which starts with fresh milk from cows in IrelandPure Bliss Organic in the 2-fluid ounce ready-to-feed bottle is the only USDA-certified organic liquid infant formula offered in select U.S. retail storesPure Bliss by Similac delivers a selection of organic or European-made infant formulas that provide gentle, compl ...
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
ZACKS· 2024-08-23 14:17
Abbott Laboratories, Inc. (ABT) recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively for patients with an Abbott HeartMate 3 heart pump, aims to provide superior clinical outcomes by eliminating aspirin as part of routine patient management.The labeling update is backed by the data from the company’s ARIES-HM3 trial and has also been approved by regulatory agencies in Canada and the European ...